U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test
04-Nov-2009
- Germany
"Validation of our Septin9 laboratory-developed test is an important step forward in providing a test that physicians can use to help them identify patients with colorectal cancer," said Jay G. Wohlgemuth, M.D., Vice President of Science and Innovation, Quest Diagnostics. "We intend to release the test in the U.S. later this year."
Topics
Organizations
Epigenomics
Quest Diagnostics
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.